Fig. 1

Study design and treatment efficacy of enrolled patients. a Key eligibility criteria and study design. b Kaplan–Meier estimates of PFS for enrolled patients. c Best response of enrolled patients. d Concordance analysis of high-frequency mutations in paired plasma and tumor tissue samples among 21 patients. e Correlation between mutation frequencies plasma samples versus tissue samples. PFS progression free survival, PR partial response, SD stable disease, PD progressive disease, NA not available